@article{3715846382334728a51a6e22ec03d136,
title = "Prevalence of neck pain in migraine and tension-type headache: A population study",
abstract = "Background: We assessed the prevalence of neck pain in the population in relation to headache. Methods: In a cross-sectional study, a total of 797 individuals completed a headache interview and provided self-reported data on neck pain.We identified migraine, TTH or both migraine and TTH (M+TTH) groups. Pericranial tenderness was recorded in 496 individuals. A total tenderness score (TTS) was calculated as the sum of local scores with a maximum score of 48. Results: The one-year prevalence of neck pain was 68.4% and higher in those with vs. without primary headache (85.7% vs. 56.7%; adjusted OR 3.0, 95% CI 2.04.4, p<0.001). Adjusting for age, gender, education and poor self-rated health, in comparison with those without headaches, the prevalence of neck pain (56.7%) was significantly higher in those with MTTH (89.3%), pure TTH (88.4%) and pure migraine (76.2%) (p<0.05 for all three group comparisons). Individuals with neck pain had higher TTS than individuals without neck pain (15.1±10.5 vs. 8.4±8.0, p<0.001). Conclusions: Neck pain is highly prevalent in the general population and even more prevalent in individuals with primary headaches. Prevalence is highest in coexistent M+TTH, followed by pure TTH and migraine. Myofascial tenderness is significantly increased in individuals with neck pain.",
keywords = "Neck pain, migraine, population, prevalence, tenderness, tension-type headache",
author = "Sait Ashina and Lars Bendtsen and Lyngberg, {Ann C.} and Lipton, {Richard B.} and Nazrin Hajiyeva and Rigmor Jensen",
note = "Funding Information: This work was supported by grants from the East Denmark Health Science Research Forum, the Danish Medical Association Research Fund, the Danish Health Insurance Foundation, the Danish Hospital Foundation for Medical Research, the Danish Headache Society, the Cool Sorption Foundation, GlaxoSmithKline A/S, Merck Sharp Dohme A/S, Pfizer A/S, Lundbeck Pharma A/S and H. Lundbeck A/S. The funding sources have not been involved in conducting the study. Funding Information: Sait Ashina has received honoraria for lecturing from Allergan, Nautilus Neurosciences and Neurogesx and served as a consultant for Depomed. Lars Bendtsen has received honoraria for lectures from MSD, Allergan and Pfizer and serves on the scientific advisory board for Berlin-Chemie. Richard Lipton receives research support from the National Institutes of Health (NIH) (PO1 AG03949 (program director), RO1AG025119 (investigator), RO1AG022374-06A2 (investigator), RO1AG034119 (investigator), RO1AG12101 (investigator), K23AG030857 (mentor), K23NS05140901A1 (mentor), and K23NS47256 (mentor)), the National Headache Foundation, and the Migraine Research Fund; serves on the editorial board of Neurology; has reviewed for the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke (NINDS); holds stock options in eNeura Therapeutics; and serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Pfizer, and Vedanta. R. Jensen has received honoraria for lectures and patient leaflets from MSD, Berlin-Chemie Menarini, ATI and Pfizer, and serves on medical advisory boards for LindeGas, ATI and ElectroCore. Ann C Lyngberg and Nazrin Hajiyeva have nothing to declare. Acknowledgments Publisher Copyright: {\textcopyright} International Headache Society 2014.",
year = "2015",
month = mar,
day = "26",
doi = "10.1177/0333102414535110",
language = "English (US)",
volume = "35",
pages = "211--219",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "3",
}